Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for Rocket Pharmaceuticals (RCKT). Shares have added about 6% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Rocket Pharmaceuticals due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent drivers for Rocket Pharmaceuticals, Inc. before we dive into how investors and analysts have reacted as of late.

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Sales Nil

Rocket Pharmaceuticals reported earnings of $1.08 per share (including certain one-time items) in the second quarter of 2026, in contrast to a loss of 62 cents per share incurred in the year-ago quarter.

Excluding these one-time items, the company reported a loss of 40 cents per share in the second quarter of 2026 compared to a loss of 59 cents per share reported in the year-ago quarter. The Zacks Consensus Estimate for the company’s bottom line was pegged at earnings of 28 cents per share.

Rocket Pharmaceuticals did not record any revenues in the second quarter of 2026. However, the Zacks Consensus Estimate for the company’s top line was $1 million.

Quarter in Detail

In the reported quarter, general and administrative expenses declined by around 30.4% year over year to $17.4 million, owing to lower legal expenses and other expenses.

Research and development expenses were $29.5 million, down 30.9% from the year-ago quarter’s figure. The decrease was primarily driven by lower manufacturing and development costs and certain other costs.

As of June 30, 2026, Rocket Pharmaceuticals had cash, cash equivalents and investments of $283.7 million compared with $144.4 million as of March 31, 2026. Management noted that the company’s current cash position reflects the proceeds from the sale of the Rare Pediatric Disease Priority Review Voucher.

How Have Estimates Been Moving Since Then?

In the past month, investors have witnessed a upward trend in fresh estimates.

The consensus estimate has shifted 6.8% due to these changes.

VGM Scores

At this time, Rocket Pharmaceuticals has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Charting a somewhat similar path, the stock has a score of F on the value side, putting it in the lowest quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Rocket Pharmaceuticals has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

Rocket Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, CRISPR Therapeutics AG (CRSP), a stock from the same industry, has gained 1.3%. The company reported its results for the quarter ended June 2026 more than a month ago.

CRISPR Therapeutics reported revenues of $10.18 million in the last reported quarter, representing a year-over-year change of +1043.8%. EPS of -$0.94 for the same period compares with -$1.29 a year ago.

For the current quarter, CRISPR Therapeutics is expected to post a loss of $1.06 per share, indicating a change of +9.4% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for CRISPR Therapeutics. Also, the stock has a VGM Score of F.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research